Alector (ALEC)
(Delayed Data from NSDQ)
$5.25 USD
-0.09 (-1.69%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $5.26 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Alector, Inc. [ALEC]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Live From AD/PD Lisbon 2024-Microglia Plays a Crucial Role in Amyloid Cascade
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Secret to Being a Centenarian Without Dementia Lies with the Lysosomes - Live from AD/PD 2024 Lisbon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Plasma Biomarkers in INVOKE-2 Are Crucial to Understand AL002s MOA
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
INFRONT-2 Data Hints of a Broader Role of PGRN in Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL002 is Biologically Active-Our Thoughts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Alector Pushes the Pedal on INFRONT-3, Completing Enrollment for FTD-GRN Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from CTAD 2023¯Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL002 Might Do More Than Removing Abeta; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Activating Microglia Might Reduce Plaque and Impact Phospho Tau Biomarkers-Thoughts on INVOKE-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
A Small Fragment of PGRN Might Be Enough to Slow Down Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Accelerating the Pace of INFRONT-3-Our Thoughts; Reit. Buy and $41 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
TREM2 is the Most Prized Target in the Post-Lecanemab World; Reit Buy and PT $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL044 Reinforces Alectors Neuroinflammation Targeting Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
A Direct Phase 2B for AL001s ALS Program Might Be the Right Decision-Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
All You Wanted to Know About TREM2 But Were Afraid to Ask-Hangover From Barcelona
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Do You Know About the Current State-of-the-Art AD/PD Biomarkers?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Two Different Trials Show AL001 Reduce Neuroinflammation and Slow Disease Progression
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A